{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for benzyl root_names_name in Any Name (approximate match)
Status:
US Previously Marketed
Source:
ANALEXIN PHENYRAMIDOL HYDROCHLORIDE by MALLINCKRODT
(1961)
Source URL:
First approved in 1960
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
PHENYRAMIDOL (ANALEXIN®), also known as fenyramidol, is an aminopyridine derivative, used as analgesic and muscle relaxant. It is considered as a drug that possibly causes hepatotoxicity.
Status:
US Previously Marketed
Source:
NADOLOL AND BENDROFLUMETHIAZIDE by IMPAX LABS
(2007)
Source URL:
First approved in 1959
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Bendroflumethiazide (INN), formerly bendrofluazide (BAN) is a thiazide diuretic used to treat hypertension. CORZIDE (Nadolol and Bendroflumethiazide Tablets) for oral administration combines two antihypertensive agents: CORGARD (nadolol), a nonselective beta-adrenergic blocking agent, and NATURETIN (bendroflumethiazide), a thiazide diuretic-antihypertensive. Bendroflumethiazide works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Thiazides do not affect normal blood pressure. Onset of action of thiazides occurs in two hours and the peak effect at about four hours. Duration of action persists for approximately six to 12 hours. Thiazides are eliminated rapidly by the kidney.
Status:
US Previously Marketed
First approved in 1959
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Isoxsuprine (used as isoxsuprine hydrochloride) is a drug used as a vasodilator in humans (under the trade name Duvadilan) and equines. Isoxsuprine is a β2 adrenoreceptor agonist that causes direct relaxation of uterine and vascular smooth muscle via β2 receptors. Isoxsuprine it is used in humans for treatment of premature labor, i.e. a tocolytic, and as a vasodilator for the treatment of cerebral vascular insufficiency, Raynaud's phenomenon, and other conditions. Isoxsuprine may increase the heart rate, cause changes in blood pressure, and irritate the GI tract. It should, therefore, be used with caution if combined with other drugs that affect blood pressure, such as sedatives and anesthetic drugs. Isoxsuprine is most commonly used to treat hoof-related problems in the horse, most commonly for laminitis and navicular disease, as its effects as a vasodilator are thought to increase circulation within the hoof to help counteract the problems associated with these conditions.
Status:
US Previously Marketed
Source:
ARLIDIN NYLIDRIN HYDROCHLORIDE by USV
(1961)
Source URL:
First approved in 1955
Class (Stereo):
CHEMICAL (UNKNOWN)
Targets:
Nylidrin (Buphenine, Arlidin) is a beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor. In peripheral vascular disorders, Arlidin (nylidrin HCl) increases walking ability and promotes healing of trophic ulcers. Nylidrin hydrochloride acts predominantly by beta-receptor stimulation. Beta stimulation with nylidrin has been demonstrated in a variety of isolated tissues from rabbits, guinea pigs and dogs. It has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat and in unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of actions is a greater blood supply to ischemic tissues, with usually minimal change in blood pressure. Arlidin may be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders. Short-term (3 months’ duration) and long-term (12 months’ duration) clinical studies have demonstrated a modest improvement in ability to perform general activities of daily living, self-care and in a capability for social interactions. The mechanism whereby nylidrin may provide relief of selected symptoms in some elderly patients with organic brain disorders is not known.
Status:
US Previously Marketed
First approved in 1952
Source:
CYCLAINE by MERCK
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Hexylcaine hydrochloride, a benzoic acid ester, is a local anaesthetic that has been used for surface anaesthesia of mucous membranes. Local anesthetics produce a transient block of nerve conduction by interfering with sodium channels. This effect of the anesthetic interferes with the development of an action potential across the nerve.
Status:
First approved in 1952
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Beclamide (N-benzyl-B-chloropropionamide) is a drug that possesses anticonvulsant activity. It is no longer used. It has been used as a sedative and as an anticonvulsant. Beclamide has been used in the management of both epilepsy and behavioral disorders associated with epilepsy. It was introduced into clinical practice in 1952 under the brand names Hibicon, Lederle and later it was withdrawn. This agent was shown to be effective in grand mal but not absence seizures. Early claims emphasized its safety, and it is not entirely clear why it was withdrawn from therapy for epilepsy. Interest in the drug was rekindled in the 1990s as an adjunct in the treatment of schizophrenia.
Status:
US Previously Marketed
Source:
POLOCAINE W/ LEVONORDEFRIN by DENTSPLY PHARM
(1988)
Source URL:
First approved in 1952
Source:
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN by EASTMAN KODAK
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. It is administered in a pre-mixed solution with local anesthetics, such as mepivacaine or procaine.
Status:
US Previously Marketed
Source:
TRIPELENNAMINE HYDROCHLORIDE by WATSON LABS
(1973)
Source URL:
First approved in 1948
Source:
PBZ by NOVARTIS
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Tripelennamine (sold as Pyribenzamine by Novartis) is a drug that is used as an antipruritic and first-generation antihistamine. Histamine acting on H1-receptors produces vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Tripelennamine can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as newer antihistamines have replaced it.
Status:
US Previously Marketed
Source:
SURFACAINE by LILLY
(1961)
Source URL:
First approved in 1948
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Cyclomethycaine (also known as Surfacaine) is a local anesthetic.
Status:
US Previously Marketed
Source:
THALAMYD by SCHERING
(1961)
Source URL:
First approved in 1948
Class (Stereo):
CHEMICAL (ACHIRAL)